NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

Novartis said Friday that it expects core operating profit--one of its preferred metrics, which strips out exceptional items--for 2025 to grow in the high-single-digit to low-double-digit range and ...

Novartis expects profit and sales to grow further this year after beating analysts' expectations in the fourth quarter, boosted by revenue from its key drugs.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.

Leqvio sales skyrocketed 83% to $223 million ... driven mainly by emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...